VELCADE (bortezomib) has received Health Canada approval for treatment of multiple myeloma, a fatal form of blood cancer. As part of combination therapy, VELCADE has been indicated for the treatment of patients who are suffering from previously untreated multiple myeloma and are unsuitable for stem cell transplantation. Following this approval, patients with multiple myeloma can now receive VELCADE earlier that may prove helpful in slowing the progression of the disease. Multiple myeloma is an aggressive disease that advances very swiftly, with the patient’s condition worsening exponentially.